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Abstract 
 
AGAT and GAMT, the two enzymes of the creatine synthesis pathway, are well expressed 
within CNS, suggesting autonomous brain creatine synthesis. This contradicts SLC6A8 
deficiency, which causes creatine deficiency despite CNS expression of AGAT and GAMT. 
We hypothesized that AGAT and GAMT were not co-expressed by brain cells, and that 
guanidinoacetate must be transported between cells to allow creatine synthesis. We finely 
analyzed the cell-to-cell co-expression of AGAT, GAMT and SLC6A8 in various regions of 
rat CNS, and showed that in most structures, cells co-expressing AGAT+GAMT (equipped 
for autonomous creatine synthesis) were in low proportions (<20%). Using reaggregating 
brain cell cultures, we also showed that brain cells take up guanidinoacetate and convert it to 
creatine. Guanidinoacetate uptake was competed by creatine. This suggests that in most brain 
regions, guanidinoacetate is transported from AGAT- to GAMT-expressing cells through 
SLC6A8 to allow creatine synthesis, thereby explaining creatine deficiency in SLC6A8-
deficient CNS. 
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Introduction 
 
In mammals, creatine (Cr) is taken from diet or synthesized by a two-step mechanism 
involving L-arginine:glycine amidinotransferase (AGAT) yielding guanidinoacetate (GAA) as 
intermediate, and guanidinoacetate methyltransferase (GAMT) converting GAA to Cr. Cells 
take up Cr through a specific transporter, SLC6A8 (Wyss & Kaddurah-Daouk, 2000). 
 
Central nervous system (CNS) is the main organ affected in Cr deficiency syndromes caused 
by AGAT, GAMT or SLC6A8 deficiency (Stöckler et al., 1994; Schulze et al., 1997; 
Salomons et al., 2001; Item et al., 2001). These patients present neurological symptoms in 
infancy, including mental retardation and delays in speech acquisition. GAMT, and often 
SLC6A8 deficiencies, also cause epilepsy. Cr deficiencies are characterized by strongly 
decreased Cr levels in CNS, as measured by magnetic resonance spectroscopy (MRS). 
AGAT- and GAMT-deficient patients can be treated with oral Cr supplementation, while Cr 
supplementation of SLC6A8-deficient patients does not restore brain Cr (Stöckler et al., 2007; 
Schulze & Battini, 2007). 
 
Brain cells synthesize Cr, as shown in organotypic cultures (Braissant et al., 2002; Almeida et 
al., 2006). In vivo, AGAT and GAMT are found in all brain cell types (neurons, astrocytes, 
oligodendrocytes); SLC6A8 is expressed in neurons and oligodendrocytes but not in 
astrocytes, and is present in microcapillary endothelial cells (MCEC) forming blood brain 
barrier (BBB) (Braissant et al., 2001a; Ohtsuki et al., 2002; Schmidt et al., 2004; Tachikawa 
et al., 2004). Apart of BBB, astrocyte feet around MCEC are more and more recognized as 
true regulators of water and metabolite exchanges between periphery and CNS (Nedergaard et 
al., 2003). SLC6A8 absence from astrocytes suggested thus that BBB has a limited 
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permeability for Cr (Braissant et al., 2001a). This is supported in vivo: the blood to brain Cr 
transport appears relatively inefficient in rodents (Ohtsuki et al., 2002; Perasso et al., 2003) 
and the replenishement of CNS Cr pools in AGAT- and GAMT-deficient patients 
supplemented with high doses of Cr is slow and only partial (Schulze & Battini, 2007). 
Moreover, Cr levels are normal in CSF of SLC6A8-deficient patients unable of Cr import 
from periphery, while they are strongly decreased in CSF of GAMT-deficient patients who 
can import Cr from periphery (Braissant & Henry, 2008). 
 
These observations suggest that CNS depends more on autonomous Cr synthesis than on 
supply from periphery. This seems contradictory with SLC6A8-deficient patients who, 
despite AGAT and GAMT expression in CNS, show strongly decreased levels of brain Cr. 
We hypothesized that the brain cell-to-cell AGAT, GAMT and SLC6A8 expression pattern 
might explain this contradiction: AGAT and GAMT, which can be found in every CNS cell 
types, might not be co-expressed within the same cells. That would also imply that GAA must 
be transported between brain cells for Cr synthesis to occur. This work aimed at dissecting the 
cell-to-cell co-expression of AGAT, GAMT and SLC6A8 within various regions of rat CNS. 
Moreover, brain cell GAA uptake and its conversion to Cr were analyzed by tandem mass 
spectrometry in reaggregated brain cell primary cultures, which synthesize Cr and express 
AGAT, GAMT and SLC6A8 as CNS in vivo (Braissant et al., 2008). 
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Materials and Methods 
 
Preparation of adult rat brains 
Animal procedures were in compliance with the directives of the Swiss Academy of Medical 
Science. Adult rats (Sprague-Dawley, 300g, Harlan, Netherlands) were sacrificed by 
decapitation. Their brain was extracted within 2min, rinsed in diethylpyrocarbonate-treated 
PBS, and immediately embedded in tissue freezing medium (Tissue-Tek, Sakura Finetek, 
Netherlands), frozen in liquid nitrogen-cooled isopentane and stored at –80°C. 
 
In situ hybridization and immunohistochemistry 
AGAT, GAMT and SLC6A8 expression was analyzed within various representative regions 
of the rat brain (Figure 1 and Supplementary Table 1) by in situ hybridization (ISH) coupled 
to immunohistochemistry, allowing the detection of both mRNA and protein for AGAT, 
GAMT and SLC6A8 genes. To achieve this, specific RNA probes and antibodies were 
applied to rat brain cryosections (12µm thick). ISH was performed by hybridizing 
digoxigenin-labeled antisense and sense riboprobes specific for rat AGAT, GAMT and 
SLC6A8 as described in details (Braissant et al., 2001a). Sections were stained with alkaline-
phosphatase using nitroblue-tetrazolium and 5-bromo-4-chloro-3-indolyl-phopshate (blue 
signal). After staining, sections were dehydrated. The hybridization specificity was 
ascertained by the negative staining of ISH sense control probes-hybridized sections for 
AGAT, GAMT and SLC6A8 (data not shown). Sense probes-hybridized sections were 
mounted (Eukitt, O.Kindler, Germany). Antisense probes-hybridized sections were processed 
for immunohistochemistry as described in details (Braissant, 2004), using specific anti-
AGAT, -GAMT and -SLC6A8 rabbit polyclonal antibodies already characterized (Braissant 
et al., 2005), or alternatively anti-glial fibrillary acidic protein (GFAP) or anti-NeuN mouse 
monoclonal antibodies (Chemicon International). Sections were stained using horse radish 
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peroxidase, the Histostain-Plus kit (Zymed Laboratories) and aminoethyl-carbazole/H2O2 (red 
signal). 
 
 
The double-stained sections (ISH blue, immunohistochemistry red) were mounted in glycerol. 
AGAT, GAMT and SLC6A8 patterns were considered specific and validated by the excellent 
correlation, in all CNS regions, between signals observed by ISH (mRNA) and 
immunohistochemistry (protein), the negative signals observed with ISH sense probes, and 
the absence of labeling in immunohistochemical controls without primary antibodies or in 
presence of pre-immune serum (data not shown, and Braissant et al., 2005). The ISH protocol 
sensitivity, which can detect as low as 15 transcripts per cell, has been described elsewhere 
(Braissant et al., 2001b; Braissant, 2004).  
 
Histological analysis and cell counting 
Sections were observed on an Olympus BX50 microscope equipped with a ColorView-II 
camera (Olympus Opticals, Japan). Brain structures were identified according to Paxinos and 
Watson (1986) (Supplementary Table 1). In each brain structure, cells were counted within a 
square surface of 200µm  160µm (12µm thick cryosections), except for CA3 pyramids and 
dentate gyrus granular neurons (hippocampus), and for Purkinje neurons (cerebellum), where 
cells were counted along 200µm (hippocampus) or 500µm (Purkinje neurons) of these linear 
structures. Cell counting was achieved with the help of the CellF software (Olympus). The 
average number of cells counted per brain and per co-labeling experiment is indicated in 
Supplementary Table 1. While AGAT, GAMT and SLC6A8 proteins can be localized far 
from soma (e.g: cell processes), they are also present, when expressed, in soma (AGAT and 
GAMT) or at its surface (SLC6A8) (Tachikawa et al., 2004; Braissant et al., 2008; Tachikawa 
et al., 2008). Therefore, to be coherent with ISH counting (mRNA, essentially localized 
around nucleus), brain cells were counted positive for AGAT, GAMT or SLC6A8 proteins 
 
 
         7 
only if their soma showed the immunohistochemistry signal. 
 
The 3 different “2 by 2” combinations (AGAT+GAMT; AGAT+SLC6A8; GAMT+SLC6A8) 
were unraveled in each brain analyzed (n=3; 2 females, 1 male). For each combination, 
mRNA n°1 was revealed by ISH coupled to immunohistochemistry for protein n°2, followed 
on adjacent section by ISH detection of mRNA n°2 coupled to immunohistochemistry for 
protein n°1. Particular care was taken to consider identical cells on adjacent sections. All 
combinations were repeated twice, allowing, for each brain, a total of 4 labeling “2 by 2” of 
each combinations of the 3 genes (12 adjacent sections covering 144µm depth of brain 
parenchyma). The series of (co-)labeling, distributed among the three rat brains used, were 
designed to allow the observation of the largest neuronal soma, by the continuous observation 
of each of the three genes through a depth of 96 µm (i.e.: 8 adjacent sections). With each “2 
by 2” combination and for each brain structure, the cell proportions with no expression of 
genes 1 or 2, expression of gene 1 only, expression of gene 2 only, or co-expression of genes 
1 and 2, were obtained (= values xi, also defined in Supplementary Tables 2 and 3). Each 
combination of “2 by 2” co-labeling (n = 4) gave extremely coherent results (see standard 
deviations in Supplementary Table 3). Thus, for each gene in each couple of genes, in each of 
the 10 different brain regions analyzed from 3 different rat brains, mRNA and protein data 
gave identical proportions: When a specific mRNA was detected on one slice, its respective 
protein was always detected also in the same cell on the adjacent slice, and no presentation of 
mRNA without its respective protein occurred. Conversely, when a specific protein was 
detected on one slice, its respective mRNA was always detected also in the same cell on the 
adjacent slice, and no presentation of protein without its respective mRNA occurred. Thus, 
these very coherent data between mRNA (perinuclear region) and protein (considered only in 
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the cell soma) validated the gene expression observation in the brain cell soma as truly 
representative of expression in the whole brain cells. 
 
This allowed then the determination of AGAT, GAMT and SLC6A8 (co-)expression patterns 
taken “3 by 3” (AGAT+GAMT+SLC6A8 co-expression; see below). 
 
The determination of the “3 by 3” AGAT+GAMT+SLC6A8 co-expression proportions (= 
values yj, also defined in Figure 1B and Supplementary Table 2) was obtained using two 
different approaches: 
 
The first consisted in determining the smallest intervals containing each of the y1 to y8 “3 by 
3” expression proportions. To achieve this, we determined xi as the lowest x1-x12 experimental 
measure in each brain structure. We chose one of the two yj unknowns giving xi as sum, to 
express all the other y1 to y8 unknowns, allowing finally the determination of the smallest 
intervals fitting for y1 to y8 (see their complete determination, illustrated for dentate gyrus, in 
Supplementary Table 3). These intervals are presented in the left columns of Figure 3 A, B 
and C (“experimental”). 
 
The second was based on the hypothesis, true or not, that AGAT, GAMT and SLC6A8 might 
be expressed independent of each other in brain cells, both at transcriptional and translational 
levels. y1 to y8 were calculated, in each brain structure, by developing, based on Figure 1 and 
Supplementary Table 2, the following equations, exemplified here for y2 (AGAT only) : 
 
1) y2 = x2 – y6 = x2 – [y6 / (y2 + y6) * (y2 + y6)]. 
 
Then, if (and only if) AGAT, GAMT and SLC6A8 genes are expressed independent of each 
other in the brain, both at transcriptional and translational levels : 
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2) y6 / (y2 + y6) = (y6 + y8) / (y2 + y6 + y5 + y8). 
 
After replacement of “y6/(y2 + y6)” in 1) : 
 
3) y2 = x2 – [(y6 + y8) / (y2 + y6 + y5 + y8) * (y2 + y6)] = x2 – [x8 / (x8 + x6) * x2]. 
 
For each yj, 3 different (but equivalent) equations can be developed, the 2 equations 
remaining for y2 being: 
 
4) y2 = x6 – y5 = x6 – [x10 / (x10 + x9) * x6], 
5) y2 = x9 – y1 = x9 – [x1 / (x1 + x2) * x9], 
 
By analogy, the same calculation procedure was applied to y1 and y3 to y8 (see their complete 
calcultation, illustrated for dentate gyrus, in Supplementary Table 4). yj values for each brain 
structure using this second method is presented in the right columns of Figure 3 A, B and C 
(“calculated”). 
 
 
 
Reaggregated brain cell cultures 
Reaggregated brain cell primary cultures were prepared from mechanically dissociated 
telencephalon of 16-day rat embryos, grown in serum-free, Cr-free, chemically-defined 
medium (Braissant et al., 2008). These cultures develop with neurons, astrocytes and 
oligodendrocytes organized in a 3D network acquiring a tissue-specific pattern resembling 
that of the in vivo brain, and are therefore considered as organotypic brain cell cultures 
(Honegger and Monnet-Tschudi, 2001; Cagnon and Braissant, 2007). These cultures express 
AGAT, GAMT and SLC6A8 in the same cells as in vivo brain and synthesize their own Cr, 
suggesting that they behave as in vivo CNS for Cr synthesis and transport (Braissant et al., 
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2008). Brain cell aggregates were grown for 13 days in vitro (DIV), then exposed for 12h or 
24h to various concentrations of GAA (GAA or 13C2-GAA; 200, 600 or 1000µM) and/or Cr 
(Cr or 13C-Cr; 200 or 1000µM). Aggregates were harvested at DIV13.5 (12h exposure) or 
DIV14 (24h exposure), washed three times with ice-cold PBS, frozen in liquid nitrogen, and 
stored at -80°C. 
 
Creatine and guanidinoacetate determination, and GAMT activity 
Brain cell aggregates were homogenized in H2O at 4°C using a FastPrep Cell Disrupter 
(Qbiogene, France) and centrifuged (10'000g, 5min, 4°C). The supernatant was used to 
measure Cr and GAA by electrospray tandem mass spectrometry, as described in details 
(Braissant et al., 2008).  D3-Cr (CDN Isotopes, Canada) and 
13C2-GAA (Dr Herman J ten 
Brink, Amsterdam, Netherlands) were used as internal standards. Cr and GAA were purified 
by micro solid phase extraction (Oasis MCX Elution Plate, Waters, MA USA). Separation of 
Cr and GAA was achieved at 30°C using an Atlantis HILIC silica 2.1 x 50mm 3 m (Waters, 
MA USA). The column effluent was monitored using a Triple Quadrupole TSQ Quantum 
Discovery (Thermo Scientific, CA USA). The instrument was equipped with an electrospray 
interface and was controlled by the Xcalibur software (Thermo Scientific, CA USA). Samples 
were analyzed in positive ionization mode operating in a cone voltage of 4kV. The tandem 
mass spectrometer was programmed using the selected reaction monitoring mode (SRM) to 
allow the [MH+] ions of Cr and GAA respectively at m/z 132 and 118 and that of the internal 
standards D3-Cr and 
13C2-GAA at m/z 135 and 120 to pass through the first quadrupole (Q1) 
and into the collision cell (Q2). The daughter ions for Cr and GAA are of m/z 90 and 76 
respectively, and of m/z 93 and 78 for D3-Cr and 
13C2-GAA respectively. Calibration curves 
were computed using the peak area ratio of analytes and internal standards. 
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For GAA uptake, brain cell aggregates were incubated for 12h or 24h with 200 or 600 M 
GAA. Intracellular GAA was measured as described above using SRM with the transition of 
m/z 118 to m/z 76. For Cr uptake, brain cell aggregates were incubated for 12h in presence of 
200 M 13C-Cr (Cambridge Isotope Laboratories, MA USA). Intracellular 13C-Cr was 
measured as above using SRM with transition of m/z 133 to m/z 91. The relative abundance 
of m/z 133 calculated at a ratio of 3.8 % of endogenous Cr was deduced from the measured 
transported 13C-Cr. Uptakes of GAA and 13C-Cr (12h incubation, 200µM) were competed by 
5-fold excess (1mM) of Cr and GAA, respectively. 
 
GAMT activity of brain cell aggregates in vivo was accessed by the synthesis of endogenous 
13C2-Cr when incubated with 
13C2-GAA (12h incubation, 200 M 
13C2-GAA). Newly 
synthesized 13C2-Cr was measured using SRM with transition of m/z 134 to m/z 92. 
 
Statistical analysis 
The statistical significance of intracellular GAA and Cr variations (Figure 6) was evaluated by 
Student’s T test. p<0.05 was considered significant. Data were expressed as mean  standard 
deviation. 
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Results 
 
Using ISH coupled to immunohistochemistry, the 3 different “2 by 2” combinations 
(AGAT+GAMT; AGAT+SLC6A8; GAMT+SLC6A8) were unraveled on adjacent sections of 
the rat brain. For each combination, mRNA n°1 was revealed by ISH coupled to 
immunohistochemistry for protein n°2, followed on adjacent section by ISH detection of 
mRNA n°2 coupled to immunohistochemistry for protein n°1. Particular care was taken to 
consider identical cells on adjacent sections. When a specific mRNA was detected on one 
slice, its respective protein was always detected also in the same cell on the adjacent slice, and 
no presentation of mRNA without its respective protein occurred. Conversely, when a specific 
protein was detected on one slice, its respective mRNA was always detected also in the same 
cell on the adjacent slice, and no presentation of protein without its respective mRNA 
occurred. 
 
AGAT, GAMT and SLC6A8 are expressed independent of each other in rat CNS 
Two different approaches were used to determine the “3 by 3” AGAT+GAMT+SLC6A8 co-
expression proportions (= yj; as also defined in Figure 1B and Supplementary Figure 2) of 
brain cells. The 1st was the simple estimation of the minimal interval containing each yj 
proportion based on the direct measure (= cell counting) of the “2 by 2” AGAT, GAMT and 
SLC6A8 co-expression proportions (= xi; as also defined in Supplementary Figure 2). The 2
nd 
was based on the hypothesis, true or not, that AGAT, GAMT and SLC6A8 might be 
expressed independent of each other in brain cells, both at the level of transcription and 
translation. This hypothesis allowed to calculate the “3 by 3” expression proportions (yj) from 
the “2 by 2” expression proportions (xi). Two strikingly identical expression patterns were 
found using these two independent approaches (Figure 3 A, B and C), in each brain structure 
analyzed. As the 1st approach is a true measure of the “3 by 3” expression proportions, and as 
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the 2nd approach is valid only if AGAT, GAMT and SLC6A8 are expressed independent of 
each other, we conclude that in rat CNS, AGAT, GAMT and SLC6A8 genes are expressed 
independent of each other, both at the level of transcription and translation. 
 
Four different AGAT, GAMT and SLC6A8 co-expression patterns were found depending of 
brain structures (Figures 2 and 3). Figures 2, 3, 4 and 5, as well as Supplementary Tables 1, 3 
and 4, show the data from one representative adult rat brain, the same patterns having been 
obtained in two other adult rat brains. 
 
Cortex, inferior colliculus and cerebellum (molecular layer and deep medial cerebellar 
nucleus) 
In cortex (layer V), 31% of brain cells were silent for AGAT, GAMT or SLC6A8 (Figures 
2BEF and 3A). Cells expressing AGAT, GAMT or SLC6A8 alone were 15%, 14% and 14% 
respectively. Cells co-expressing AGAT and GAMT (but not SLC6A8) were 8%, cells 
expressing AGAT and SLC6A8 (but not GAMT) were 7%, and cells co-expressing GAMT 
and SLC6A8 (but not AGAT) were 8%. Finally, cells co-expressing AGAT, GAMT and 
SLC6A8 were 4%. Thus, in cortex, cells silent for the three genes were 31%, cells equipped 
for autonomous Cr synthesis (AGAT+GAMT) were 12%, and cells equipped for Cr synthesis 
from imported GAA (SLC6A8+GAMT) were 12%. Cells with only SLC6A8 (“users” of Cr, 
but not participating to its synthesis) were 14%. 
 
Similar expression patterns were found in inferior colliculus as well as in cerebellar molecular 
layer and deep medial nucleus (Figure 3A). In inferior colliculus, cells silent for the three 
genes were 33%, cells equipped for autonomous Cr synthesis were 14%, and cells equipped 
for Cr synthesis from imported GAA were 16%. Cells with only SLC6A8 were 12%. In 
molecular layer of cerebellum, cells silent for the three genes were 32%, cells equipped for 
autonomous Cr synthesis were 18%, and cells equipped for Cr synthesis from imported GAA 
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were 17%. Cells with only SLC6A8 were 9%. In deep medial nucleus of cerebellum, cells 
silent for the three genes were 21%, cells equipped for autonomous Cr synthesis were 22%, 
and cells equipped for Cr synthesis from imported GAA were 26%. Cells with only SLC6A8 
were 11%. 
 
Hippocampus (CA3 and dentate gyrus granular neurons) and hypothalamus 
Hippocampus (neurons of CA3 layer and dentate gyrus) and ventromedial nucleus of 
hypothalamus presented similar patterns (Figures 2CD and 3B). In hippocampal CA3 layer, 
40% of neurons co-expressed AGAT, GAMT and SLC6A8, 20% being silent for the three 
genes. 47% of cells were equipped for autonomous Cr synthesis, cells equipped for Cr 
synthesis from imported GAA were 49%, and cells with SLC6A8 only were 6%. In granular 
neurons of dentate gyrus, 32% of cells co-expressed AGAT, GAMT and SLC6A8, 35% being 
silent for the three genes. 38% of cells were equipped for autonomous Cr synthesis, cells 
equipped for Cr synthesis from imported GAA were 37%, and cells with SLC6A8 only were 
5%. In hypothalamic ventromedial nucleus, 29% of cells co-expressed AGAT, GAMT and 
SLC6A8, 30% being silent for the three genes. 37% of cells were equipped for autonomous 
Cr synthesis, cells equipped for Cr synthesis from imported GAA were 37%, and cells with 
SLC6A8 only were 4%. 
 
Purkinje neurons 
37% of Purkinje neurons co-expressed AGAT, GAMT and SLC6A8, 9% only being silent for 
the three genes. 61% of Purkinje neurons were equipped for autonomous Cr synthesis, cells 
equipped for Cr synthesis from imported GAA were 44%, and cells with SLC6A8 only were 
5% (Figure 3B). 
 
Caudate putamen and pons (parvocellular reticular nucleus) 
Caudate putamen and parvocellular reticular nucleus of pons showed very peculiar patterns 
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(Figures 2A and 3C). In caudate putamen, 50% of cells were silent for AGAT, GAMT or 
SLC6A8, and 43% expressed GAMT only. Cells equipped for autonomous Cr synthesis were 
1%, cells equipped for Cr synthesis from imported GAA were 1%, and cells with SLC6A8 
only were 2%. In parvocellular reticular nucleus of pons, 44% of cells were silent for AGAT, 
GAMT or SLC6A8, and 37% expressed AGAT only. Cells equipped for autonomous Cr 
synthesis were 7%, cells equipped for Cr synthesis from imported GAA were 5%, and cells 
with SLC6A8 only were 4%.  
 
Proportions of neurons and astrocytes expressing AGAT, GAMT and SLC6A8 in cortex 
We analyzed within layer V of cortex whether AGAT and GAMT were homogeneously 
expressed between neurons and glia. This was achieved by ISH for AGAT, GAMT or 
SLC6A8 mRNAs, coupled to immunohistochemistry for the neuronal marker NeuN or the 
astrocytic marker GFAP (Figure 4). The abovementioned cell counting method was applied to 
determine the proportion of specific cell types expressing AGAT, GAMT or SLC6A8 (Figure 
5A). We showed that only 22% of NeuN-positive neurons were positive for AGAT, while 
48% were positive for GAMT. In contrast, 55% of GFAP-positive astrocytes were positive for 
AGAT, while only 21% were positive for GAMT. 27% of NeuN-positive neurons expressed 
SLC6A8, while, as expected, no astrocyte was found expressing SLC6A8. As AGAT, GAMT 
and SLC6A8 are expressed independent of each other (see above and Figure 3), applying the 
calculation method described in Methods and Supplementary Tables 2 to 4 allowed to 
reconstitute the differential “3 by 3” AGAT+GAMT+SLC6A8 co-expression in cortical 
neurons and astrocytes (Figure 5B). We show in particular that important proportions of both 
neurons (25%) and astrocytes (35%) were silent for the three genes. Based on the 1:0.4 ratio 
of neurons versus astrocytes in the rat cortex (Nedergaard et al., 2003), we could reconstitute 
the cumulative proportions of cortical neurons and astrocytes co-expressing AGAT, GAMT 
and SLC6A8, which fitted remarkably well with the direct measure of expression ranges 
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presented in Figure 3A (Figure 5C). The slight variations between both patterns are likely due 
to other cell types present in lower proportions within cortex (oligodendrocytes, microglia), 
which were not evaluated here. 
 
Brains cells take up guanidinoacetate and convert it to creatine 
As most rat brain structures showed a high proportion of cellular dissociation between 
AGAT- and GAMT-expressing cells, we hypothesized that brain cells were able to import 
GAA, and convert it to Cr. Using rat brain cell primary cultures in aggregates, we first 
demonstrated by tandem mass spectrometry that brain cells can import GAA (Figure 6A). 
Exposure up to 200µM GAA for 12h did not disturb the endogenous Cr synthesis pathway, 
which occurs in this system as in CNS in vivo (Braissant et al., 2008); a higher GAA 
concentration (600µM) was toxic to brain cells, as shown by the 30% decrease in intracellular 
Cr (Figure 6A), as well as by axonal growth impairment and induction of apoptosis (data not 
shown). 24h GAA exposure had the same effects (data not shown). We further showed that 
imported GAA could be converted to Cr, by exposing brain cell aggregates to 13C stable 
isotope-labelled 13C2-GAA, and measuring intracellular 
13C2-Cr. After 12h exposure to 
200µM 13C2-GAA, 29% of imported 
13C2-GAA was converted to 
13C2-Cr (Figure 6B). 
Finally, we showed that 1000µM Cr completely competed GAA uptake by brain cells 
(200µM GAA exposure), with the same efficiency as 1000µM GAA competed Cr uptake 
(200µM 13C-Cr exposure, to avoid influence of the endogenous Cr synthesis pathway) (Figure 
6C). 
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Discussion 
 
Brain AGAT, GAMT and SLC6A8 are expressed independent of each other 
This work demonstrates that AGAT, GAMT and SLC6A8 are expressed independent of each 
other in CNS, at the level of transcription and translation. Cr exerts a negative pre-
translational feedback on AGAT regulation in kidney (McGuire et al., 1984). Brain appears to 
behave differently, where Cr rather alters AGAT enzymatic activity (Braissant et al., 2008). 
Human muscle behave similarly, where Cr does not influence SLC6A8 expression 
(Tarnopolsky et al., 2003). Thus, brain AGAT, GAMT and SLC6A8 expression does not 
seem influenced by their substrate or reaction products, probably allowing CNS to be 
permanently equipped with Cr synthesis and transport machineries, something crucial 
knowing that Cr is essential in CNS development and functions (Braissant & Henry, 2008; 
Andres et al., 2008). 
 
Dissociation of AGAT and GAMT, and GAA uptake by brain cells: Relevance to Cr 
deficiency syndromes 
Brain Cr was thought to come principally from periphery through BBB (Wyss & Kaddurah-
Daouk, 2000). However, mammalian CNS synthesizes Cr and express AGAT and GAMT in 
every cell types (Pisano et al., 1963; Braissant et al., 2001a; Schmidt et al., 2004; Tachikawa 
et al., 2004). SLC6A8 is expressed in CNS, but only by neurons and oligodendrocytes. The 
SLC6A8 absence from astrocytes (particularly astrocyte feet lining MCEC; Braissant et al., 
2001a; Ohtsuki et al., 2002; Tachikawa et al., 2004) made us suggest that BBB has a limited 
permeability for Cr, and that CNS depends more on autonomous Cr synthesis than on supply 
from periphery (Braissant et al., 2007; Braissant & Henry, 2008). 
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Brain autonomous Cr synthesis seems contradictory with in vivo characteristics of SLC6A8 
deficiency, which, despite normal CNS expression of AGAT and GAMT, shows no, or very 
low levels of, brain Cr by MRS, as in AGAT and GAMT deficiencies. We hypothesized that 
this apparent contradiction might be explained by brain patterns of AGAT, GAMT and 
SLC6A8, which might be expressed in a dissociated way (Braissant and Henry, 2008). 
 
This work demonstrates that in many brain structures, including these usually observed by 
MRS, cells fully equipped for Cr synthesis (co-expressing AGAT+GAMT) are <20% (cortex: 
12%, striatum: 1%), and that a higher proportion of cells expresses AGAT without GAMT, or 
GAMT without AGAT. This suggested that for Cr synthesis to occur, GAA must be 
transported from AGAT- to GAMT-expressing cells. If GAA is transported by SLC6A8 (see 
below), it would explain the absence of Cr measured by MRS in CNS of SLC6A8-deficient 
patients. This recently-proposed model (Braissant & Henry, 2008) is also supported in vivo by 
the attempt to treat SLC6A8-deficient patients with arginine to stimulate replenishment of 
their cerebral Cr pool by brain endogenous synthesis, which failed to increase CNS Cr (Fons 
et al., 2008). Thus, according to the above-mentioned hypothesis, in human brain also, GAA 
must be transported from AGAT- to GAMT-expressing cells, through SLC6A8, for Cr 
synthesis to occur. 
 
Whilst in most regions of AGAT- and GAMT-deficient brain, the MRS measure of Cr should 
show an absence or strong decrease of Cr (partly due to the lack of brain autonomous Cr 
synthesis), the situation may be more contrasted in SLC6A8 deficiency. Indeed, the MRS Cr 
measure is usually performed in cortical areas and basal ganglia (striatum), where SLC6A8-
deficient patients present an absence or strong decrease of Cr (DeGrauw et al., 2002) 
(excepted for females heterozygous for SLC6A8 mutation, who usually present a milder 
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cerebral Cr deficiency, as SLC6A8 deficiency is an X-linked disorder). If AGAT, GAMT and 
SLC6A8 patterns, as described here in rat CNS, are also true in human, a normal or only 
attenuated Cr peak should be detected in brain regions of SLC6A8-deficient patients 
presenting high proportions of cells co-expressing AGAT+GAMT, like hippocampus, 
hypothalamus or Purkinje cells. 
 
The striking patterns found for AGAT in pons and GAMT in caudate putamen are difficult to 
interprete. However, the GAMT-only expression of caudate putamen may fit with GAMT 
deficiency, which impairs striatum development (Von Figura et al., 2001). 
 
GAA uptake by brain cells, and conversion to Cr 
GAA competes for Cr uptake by SLC6A8 (Ohtsuki et al., 2002). Our work brings the first 
evidence that cells of brain parenchyma (neurons, astrocytes, oligodendrocytes) can take up 
GAA. GAA uptake was completely competed by 5-fold excess Cr, as efficiently as Cr uptake 
was competed by 5-fold excess GAA. This strongly suggests that GAA is taken up by brain 
cells through the same transporter as Cr: SLC6A8. This is in good agreement with SLC6A8 
overexpression studies in HEK293 cells and Xenopus oocytes (Tachikawa et al., 2008). 
Finally, using 13C2-GAA, our work is the first to demonstrate that GAA taken-up by brain 
cells is readily converted to Cr, in line with our hypothesis that for Cr synthesis to occur in 
CNS, GAA must be transported from AGAT- to GAMT-expressing cells. The low proportion 
of GAA conversion to Cr (29%) was due to the diluting effect of endogenous Cr synthesis 
pathway. One important question remaining to elucidate is how GAA can leave AGAT-
expressing cells to be imported by GAMT-expressing cells through SLC6A8. 
 
A recent work demonstrated GAA uptake by TR-CSFB cells (blood-CSF barrier model) and 
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isolated choroid plexus in vitro, probably by SLC6A8, but concluded that due to GAA:Cr 
ratio in CSF (1:1000; 0.015-0.560µM versus 17-90µM in human; Braissant and Henry, 2008), 
SLC6A8 was unlikely to transport GAA in choroid plexus in vivo (Tachikawa et al., 2008). Cr 
and GAA concentrations are much higher in brain parenchyma (5-6mM and 0.9-1.6mM in 
human, respectively), but nothing is known on their concentrations in extracellular fluid. In 
rat brain parenchyma, Cr was measured at 8.5mM (Renema et al., 2003), and we measured 
GAA at levels 5-10 fold lower than Cr in rat brain cell organotypic cultures (Braissant et al., 
2008; and this study). We may thus extrapolate levels of GAA in rat brain parenchyma at 
0.85-1.7mM, comparable to human. 200µM GAA, as used in this study, may thus be relevant 
in CNS extracellular fluid, at least locally, in vicinity of GAA transfer from AGAT- to 
GAMT-expressing cells.     
 
AGAT and GAMT dissociation, as well as Cr and GAA uptake in CNS: A role for 
neuromodulation? 
Dissociation of AGAT and GAMT activities between different brain cells may appear 
expensive for CNS in terms of both the energy and machinery needed to transfer GAA, and 
GAA toxicity to neurons if released in the extracellular space at too high concentrations. Cr is 
exocytotically released from central neurons (Almeida et al., 2006) and acts as partial agonist 
on central GABAA post-synaptic receptors (Koga et al., 2005), suggesting a role of co-
transmitter modulating postsynaptic GABA receptors. On the other hand, GAA can activate 
GABAA receptors in cortical and cerebellar neurons (Neu et al., 2002; Cupello et al., 2008). 
In cortex in particular, GAA can activate GABAA receptors at concentrations compatible with 
its levels in CNS extracelllar fluid (see above; and Neu et al., 2002; Braissant and Henry, 
2008). Thus, both Cr and GAA can act as neuromodulators. Keeping AGAT and GAMT 
expression separated in different brain cells might thus facilitate the fine tuning of the 
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respective synthesis of GAA and Cr for their specific roles of neuromodulation, while the 
efficient uptake of Cr and GAA by brain cells might be essential for keeping their 
extracellular concentrations in low ranges, to allow neuromodulation (Cr and GAA) while 
avoiding toxic effects of GAA.  
 
Fine tuning versus high flux of Cr synthesis and transport in the brain 
Two strikingly coherent main expression patterns are found in the different brain structures. 
In 1st one, present in most brain regions, high proportions of cells do not express either 
AGAT, GAMT or SLC6A8 (20-50%), the proportion of cells expressing SLC6A8 only (Cr 
“users”) remains below 15%, while AGAT and GAMT are not co-expressed. These 
structures, distributed throughout the whole CNS, may need the dissociation between AGAT 
and GAMT expression, as well as the low proportion of cells expressing SLC6A8, for the fine 
tuning of GAA and Cr synthesis described above, and their respective roles in 
neuromodulation. 
 
 
In 2nd one, specific structures (hippocampus, Purkinje neurons) present high proportions of 
cells co-expressing AGAT+GAMT (40-60%), and high proportions of cells expressing 
SLC6A8 (45-65%). It suggests that these neuronal layers permanently need high Cr levels, in 
line with their high creatine kinase activity (Wallimann & Hemmer, 1994; Kaldis et al., 
1996).  
 
Neuronal versus glial synthesis of creatine 
While GAMT is expressed by rat neurons and glia (Braissant et al., 2001a), data showing 
GAMT predominantly (but not exclusively) in mouse glia (Schmidt et al., 2004; Tachikawa et 
al., 2004) suggested that Cr synthesis final step may principally be glial. Brain mixed-cell or 
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astrocyte primary cultures synthesize Cr (Dringen et al., 1998; Braissant et al., 2008), but we 
also showed that neuron-enriched primary cultures synthesize Cr (Braissant et al., 2002). This 
study demonstrates that depending on brain structure, Cr synthesis may occur both in neurons 
and glia. In cortex, 48% of NeuN-positive neurons and 21% of GFAP-positive astrocytes 
expressed GAMT. CA3, dentate gyrus and Purkinje neurons were 50%-70% to express 
GAMT. Both neurons and astrocytes presented every possibility of AGAT, GAMT and 
SLC6A8 co-expression patterns (apart of SLC6A8 absence from astrocytes), and both 
neurons and astrocytes could be silent for the three genes. It is emphasized that 
oligodendrocytes, not evaluated in this study, highly express GAMT (Schmidt et al., 2004; 
Tachikawa et al., 2004; Braissant et al., 2008), and may be high Cr producers. It remains also 
to elucidate how Cr can leave “Cr producers” to be taken up by “Cr users” through SLC6A8. 
 
Conclusion 
We show that in numerous rat brain structures, including cortex and caudate putamen, AGAT 
and GAMT are expressed in a dissociated way, suggesting GAA transport from AGAT- to 
GAMT-expressing cells to allow Cr synthesis. Accordingly, this work is the first to 
demonstrate that brain cells can take up GAA probably through SLC6A8, and convert it to Cr. 
Taken together, our results explain the absence of Cr in the brain of SLC6A8-deficient 
patients, despite normal AGAT and GAMT expression. 
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Figure legends 
 
Figure 1: Rat brain structures analyzed for AGAT, GAMT and SLC6A8 co-expression. 
A: 10 different structures of the rat brain were analyzed: Cortex (layer V, Cx); caudate 
putamen (CP); hippocampus (CA3 and dentate gyrus neurons, DG); hypothalamus 
(ventromedial nucleus, VMH); inferior colliculus (IC); pons (parvocellular reticular nucleus, 
PCRt); cerebellum (molecular layer, Mol; Purkinje neurons, Pur; and deep medial nucleus, 
Med) (sagittal view of rat brain adapted from http://www.brain-map.org; lateral level for rat 
brain: 1.20 mm). B: The proportions of cells (co-)expressing AGAT alone (y2), GAMT alone 
(y3), SLC6A8 alone (y4), AGAT + GAMT (y5), AGAT + SLC6A8 (y6), GAMT + SLC6A8 
(y7), AGAT + GAMT + SLC6A8 (y8), or none (y1), were determined in each brain structures 
(see also Supplementary Tables 2, 3 and 4). 
 
Figure 2: Co-expression of AGAT, GAMT and SLC6A8 in the rat brain. In situ 
hybridization (mRNA, blue signal) coupled to immunohistochemistry (protein, red signal), 
showing “2 by 2” co-expression of (A) AGAT mRNA and GAMT protein in pons, (B) 
GAMT mRNA and AGAT protein in layer V of cortex, (C) AGAT mRNA and SLC6A8 
protein in hypothalamus, (D) SLC6A8 mRNA and AGAT protein in CA3 neurons, (E) 
GAMT mRNA and SLC6A8 protein in layer V of cortex, and (F) SLC6A8 mRNA and 
GAMT protein in layer V of cortex. Examples of cells without any labeling are indicated by 
empty arrows; examples of cells with gene 1 mRNA expression only are indicated by blue 
arrows; examples of cells with gene 2 protein expression only are indicated by red arrows; 
examples of cells with co-labeling for gene 1 mRNA and gene 2 protein are indicated by 
purple arrows. Bar: 50µm. 
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Figure 3: Co-expression of AGAT, GAMT and SLC6A8 in the different structures of the 
rat brain. A: cortex, inferior colliculus and cerebellum (molecular layer and deep medial 
nucleus). B: hippocampus (CA3 and dentate gyrus), hypothalamus (ventromedial nucleus) 
and cerebellum (Purkinje neurons). C: caudate putamen and pons (parvoreticular nucleus). 
The percentage of cells (co-)expressing AGAT alone, GAMT alone, SLC6A8 alone, 
AGAT+GAMT, AGAT+SLC6A8, GAMT+SLC6A8, AGAT+GAMT+SLC6A8, or none, is 
indicated, for both methods used (experimental and calculated) to estimate these proportions 
(see also Figure 2 for an illustration of the co-labeling used). For the experimental measure of 
co-expression proportions (left column), the ranges between minimal and maximal 
proportions are represented (open white rectangle). For the calculated proportions (right 
column), means  standard deviations (n=3) are represented. 
 
Figure 4: Expression of AGAT, GAMT and SLC6A8 in cortical neurons and astrocytes. 
In situ hybridization for AGAT (A,D), GAMT (B,E) and SLC6A8 (C,F) mRNAs (blue 
signal), coupled to immunohistochemistry for neuronal (NeuN; A-C) and astrocytic (GFAP; 
D-F) markers respectively (red signal). Examples of neurons and astrocytes without co-
labelling for AGAT, GAMT or SLC6A8 are indicated by red arrows, while examples of 
neurons and astrocytes with co-labelling for AGAT, GAMT or SLC6A8 are indicated by 
purple arrows. Bar: 50µm. 
 
Figure 5: Proportions of neurons and astrocytes expressing AGAT, GAMT and 
SLC6A8, respectively, within layer V of cortex. Cell counting as described in Material and 
Methods, from co-labeling experiments as shown in Figure 4 (ISH for AGAT, GAMT or 
SLC6A8, coupled to immunohistochemistry for NeuN or GFAP to identify neurons and 
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astrocytes, respectively). Data from a representative adult rat cortex; 6 adjacent sections 
observed for each co-labeling experiment; total number of NeuN-positive neurons: 441; total 
number of GFAP-positive astrocytes: 337. The cell percentages are based on the cumulative 
counting of the 6 adjacent sections, for each co-labeling experiment. A: proportions of cortical 
neurons, respectively astrocytes, expressing AGAT, GAMT or SLC6A8; B: reconstitution of 
the “3 by 3“ AGAT, GAMT and SLC6A8 expression pattern within cortical neurons and 
astrocytes; C: reconstitution of the cumulative, neuronal and astrocytic, “3 by 3“ AGAT, 
GAMT and SLC6A8 expression pattern, based on the ratio of 1 neuron per 0.4 astrocyte 
(Nedergaard et al., 2003). Measured ranges between minimal and maximal proportions (taken 
from Figure 3A) are shown in white rectangles, for comparison. 
 
Figure 6: Uptake of guanidinoacetate by brain cells, and conversion to creatine. Measure 
of intracellular GAA and Cr within brain cell 3D cultures (DIV13) by tandem mass 
spectrometry, after 12 h of exposure to GAA (GAA or 13C2-GAA) and/or Cr (Cr or 
13C-Cr). 
A: GAA Uptake by brain cells, and influence on endogenous Cr synthesis pathway. Cultures 
exposed for 12h to 200 and 600µM GAA, respectively, and measure of intracellular GAA and 
Cr. B: Conversion of GAA taken up by brain cells to Cr. Cultures exposed for 12h to 200µM 
13C2-GAA, and measure of intracellular 
13C2-GAA and 
13C2-Cr. C: Competition of GAA 
uptake by Cr, respectively of Cr uptake by GAA, in brain cells. Cultures exposed 12h to 
200µM GAA (  competition with 1000µM Cr), respectively 200µM 13C-Cr (  competition 
with 1000µM GAA), and measure of intracellular GAA, respectively 13C-Cr. A, B and C 
show representative experiments, with mean  standard deviations for each point of measure. 
Significant increase in GAA, respectively decrease in Cr (A) are indicated, as compared to 
control conditions (200µM GAA), respectively to control conditions and 200µM GAA (600 
µM GAA). Student’s t test; n = 3; NS: not significant; **: p<0.01; ***: p<0.001). 
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 Supplementary Table 1: 
Position of each structure observed of the rat brain, and average number of cells 
counted, per brain, in each of these structures, and for each “2 by 2” co-labeling 
experiment.a 
 
All structures : Lateral : 1.20 mm   
    
  
 
Antero-posterior : 
 
 
Dorso-ventral : 
Cells counted / brain 
/ “2 by 2” co-labeling 
experiment b 
    
Cortex (Cx) bregma –2.00 mm interaural +8.40 mm  218  6 
Caudate putamen (CP) bregma +0.60 mm interaural +4.80 mm 273  25 
Hippocampus (CA3) bregma –2.20 mm interaural +6.40 mm 136  14 
Hippocampus (DG) bregma –3.50 mm interaural +6.50 mm  534  27 
Hypothalamus (VMH) bregma –2.80 mm interaural +0.20 mm 90  3 
Inferior colliculus (IC) bregma –9.00 mm interaural +6.40 mm 170  9 
Pons (PCRt) bregma –12.20 mm interaural +1.15 mm  223  12 
Cerebellum (molecular layer) bregma –14.80 mm interaural +5.20 mm  102  4 
Cerebellum (Purkinje neurons) bregma –14.60 mm interaural +5.20 mm 38  4 
Cerebellum (Med) bregma –11.40 mm interaural +4.20 mm 119  11 
    
 
a: The position is according to Paxinos & Watson (1986; the rat brain in stereotaxic 
coordinates; London: Academic Press Limited). CA3: giant pyramidal neurons of 
Ammon’s horn 3; DG: granular neurons of dentate gyrus; Med: deep medial cerebellar 
nucleus; PCRt: parvocellular reticular nucleus (pons); VMH: ventromedial hypothalamic 
nucleus. 
b: Mean  standard deviation (n = 4). 
Supplementary Table 2: 
Proportions of (co-)labeled cells in the respective “2 by 2” co-labeling experiments 
AGAT+GAMT, AGAT+SLC6A8 and GAMT+SLC6A8 (= x1 to x12; experimental), in 
function of the “3 by 3” AGAT+GAMT+SLC6A8 unknown expression proportions (= y1 
to y8; calculated). y1: no expression of AGAT, GAMT or SLC6A8; y2: AGAT only; y3: 
GAMT only; y4: SLC6A8 only; y5: AGAT+GAMT but not SLC6A8; y6: AGAT+SLC6A8 but 
not GAMT; y7: GAMT+SLC6A8 but not AGAT; y8: AGAT+GAMT+SLC6A8 (yj are also 
defined in Figure 1B). 
 
 
 
Experiments : 
 Measured 
experimentally 
(= counted) 
Unknown 
proportions 
to determine 
    
    
 - = x1 = y1 + y4 
Co-labeling AGAT = x2 = y2 + y6 
AGAT + GAMT GAMT = x3 = y3 + y7 
 AGAT+GAMT = x4 = y5 + y8 
    
    
 - = x5 = y1 + y3 
Co-labeling AGAT = x6 = y2 + y5 
AGAT + SLC6A8 SLC6A8 = x7 = y4 + y7 
 AGAT+SLC6A8 = x8 = y6 + y8 
    
    
 - = x9 = y1 + y2 
Co-labeling GAMT = x10 = y3 + y5 
GAMT + SLC6A8 SLC6A8 = x11 = y4 + y6 
 GAMT+SLC6A8 = x12 = y7 + y8 
    
 
Supplementary Table 3: 
Experimental interval determination for the “3 by 3” AGAT+GAMT+SLC6A8 (co-
)expression proportions y1 to y8 in granular neurons of dentate gyrus (hippocampus). 
Determination of the experimental intervals (= y1 to y8; shown in left columns of Figure 3) is 
based on the experimental measure (= cell counting; xi) of the proportions of (co-)labeled 
cells in the respective “2 by 2” co-labeling experiments AGAT+GAMT, AGAT+SLC6A8 and 
GAMT+SLC6A8 (n = 4; mean ± standard deviation; see Material and Methods; xi are also 
defined in Supplementary Table 2, while yj are also defined in Figure 1B and Supplementary 
Table 2). The same method of calculation was applied for each brain structure observed. 
 
Example of hippocampus (granule neurons of dentate gyrus) [%] 
 
“2 by 2” co-labeling experiments 
AGAT + GAMT AGAT + SLC6A8 GAMT + SLC6A8 
x1 = 41.4 ± 7.8 x5 = 43.9 ± 9.9 x9 = 42.8 ± 1.3 
x2 = 9.1 ± 1.3 x6 = 9.6 ± 2.1 x10 = 10.7 ± 4.1 
x3 = 10.1 ± 2.5 x7 = 7.6 ± 0.8 x11 = 7.7 ± 2.0 
x4 = 39.4 ± 6.7 x8 = 38.9 ± 9.8 x12 = 38.8 ± 1.6 
 - x1 = y1 + y4 = 41.4 
Co-labeling AGAT x2 = y2 + y6 = 9.1 
AGAT + GAMT GAMT x3 = y3 + y7 = 10.1 
 AGAT+GAMT x4 = y5 + y8 = 39.4 
 - x5 = y1 + y3 = 43.9 
Co-labeling AGAT x6 = y2 + y5 = 9.6 
AGAT + SLC6A8 SLC6A8 x7 = y4 + y7 = 7.6 
 AGAT+SLC6A8 x8 = y6 + y8 = 38.9 
 - x9 = y1 + y2 = 42.8 
Co-labeling GAMT x10 = y3 + y5 = 10.7 
GAMT + SLC6A8 SLC6A8 x11 = y4 + y6 = 7.7 
 GAMT+SLC6A8 x12 = y7 + y8 = 38.8 
   
“3 by 3” (co-)expression interval determination, in function of y4 ( => 0  y4  7.6 ) 
y1 : - y1 = 41.4 – y4   33.8  y1  41.4 
y2 : AGAT y2 = 1.4 + y4     1.4  y2  9.0 
y3 : GAMT y3 = 2.5 + y4     2.5  y3  10.1 
Y4 : SLC6A8      0.0  y4  7.6 
y5 : AGAT+GAMT y5 = 8.2 – y4     0.6  y5  8.2 
y6 : AGAT+SLC6A8 y6 = 7.7 – y4     0.1  y6   7.7 
y7 : GAMT+SLC6A8 y7 = 7.6 – y4     0.0  y7  7.6 
y8 : AGAT+GAMT+SLC6A8 y8 = 31.2 + y4   31.8  y8  38.8 
 
 Supplementary Table 4: 
Calculation of the “3 by 3” AGAT+GAMT+SLC6A8 (co-)expression proportions y1 to 
y8, based on the hypothesis that AGAT, GAMT and SLC6A8 are expressed independent 
of each other in brain cells. For each y1 to y8 unknowns, 3 different (but equivalent) 
equations can be developed. An example is given for granular neurons of the dentate gyrus 
(hippocampus) (see also Material and Methods, as well as Figure 1B and Supplementary 
Table 2). The same method of calculation was applied for each brain structure observed. The 
means obtained (  standard deviations, are shown in right columns of Figure 3). 
 
Example of hippocampus (granular neurons of dentate gyrus) [%] 
       
y1 : -   y5 : AGAT+GAMT  
y1 = x1 – [x7/(x7+x5)*x1] 35.3  y5 = x4 – [x8/(x8+x6)*x4] 7.8 
 = x5 – [x10/(x10+x9)*x5] 35.1   = x6 – [x9/(x9+x10)*x6] 1.9 
 = x9 – [x2/(x2+x1)*x9] 35.1   = x10 – [x3/(x3+x4)*x10] 8.5 
 mean : 35.2   mean : 6.1 
       
y2 : AGAT   y6 : AGAT+SLC6A8  
y2 = x2 – [x8/(x8+x6)*x2] 1.8  y6 = x2 – [x9/(x9+x11)*x2] 1.4 
 = x6 – [x10/(x10+x9)*x6] 7.7   = x8 – [x4/(x4+x2)*x8] 7.3 
 = x9 – [x1/(x1+x2)*x9] 7.7   = x11 – [x7/(x7+x8)*x11] 6.4 
 mean : 5.7   mean : 5.0 
       
y3 : GAMT   y7 : GAMT+SLC6A8  
y3 = x3 – [x12/(x12+x10)*x3] 2.2  y7 = x3 – [x5/(x5+x7)*x3] 1.5 
 = x5 – [x1/(x1+x3)*x5] 8.6   = x7 – [x11/(x11+x12)*x7] 6.3 
 = x10 – [x6/(x6+x5)*x10] 8.8   = x12 – [x4/(x4+x3)*x12] 7.9 
 mean : 6.5   mean : 5.2 
       
y4 : SLC6A8   y8 : AGAT+GAMT+SLC6A8  
y4 = x1 – [x9/(x9+x11)*x1] 6.3  y8 = x4 – [x10/(x10+x12)*x4] 30.9 
 = x7 – [x3/(x3+x1)*x7] 6.1   = x8 – [x2/(x2+x4)*x8] 31.6 
 = x11 – [x8/(x8+x7)*x11] 1.3   = x12 – [x7/(x7+x8)*x12] 32.5 
 mean : 4.6   mean : 31.6 
 
 
